260 related articles for article (PubMed ID: 33512910)
1. Testosterone for Managing Treatment-related Fatigue in Patients With Metastatic Renal Cell Carcinoma: A Phase 2 Randomized Study FARETES.
Tsimafeyeu I; Tishova Y; Zukov R; Borisov P; Bondarenko A; Zakurdaeva K
Am J Clin Oncol; 2021 Apr; 44(4):137-142. PubMed ID: 33512910
[TBL] [Abstract][Full Text] [Related]
2. Use of targeted therapies for advanced renal cell carcinoma in the Veterans Health Administration.
Aspinall SL; Zhao X; Geraci MC; Good CB; Cunningham FE; Heron BB; Becker D; Lee S; Prasad V;
Cancer Med; 2019 Nov; 8(15):6651-6661. PubMed ID: 31536684
[TBL] [Abstract][Full Text] [Related]
3. Fatigue in renal cell carcinoma: the hidden burden of current targeted therapies.
Larkin JM; Pyle LM; Gore ME
Oncologist; 2010; 15(11):1135-46. PubMed ID: 21051659
[TBL] [Abstract][Full Text] [Related]
4. Anticancer Drugs-Related Hypogonadism in Male Patients with Advanced Cancers on Active Treatment: A Systematic Review.
Massa G; Zambelli L; Zecca E; Shkodra M; Tinè G; Caraceni A
Oncologist; 2024 Jun; 29(6):e728-e740. PubMed ID: 38518107
[TBL] [Abstract][Full Text] [Related]
5. Retrospective study of testosterone deficiency and symptom burden in patients with pancreatic cancer.
Kazarian AG; Conger HK; Mott SL; Loeffler BT; Dempewolf SM; Coleman KL; Pearlman AM; Chan CHF; Talbert EE
Transl Androl Urol; 2023 Jul; 12(7):1079-1089. PubMed ID: 37554534
[TBL] [Abstract][Full Text] [Related]
6. TRANSFORMER: A Randomized Phase II Study Comparing Bipolar Androgen Therapy Versus Enzalutamide in Asymptomatic Men With Castration-Resistant Metastatic Prostate Cancer.
Denmeade SR; Wang H; Agarwal N; Smith DC; Schweizer MT; Stein MN; Assikis V; Twardowski PW; Flaig TW; Szmulewitz RZ; Holzbeierlein JM; Hauke RJ; Sonpavde G; Garcia JA; Hussain A; Sartor O; Mao S; Cao H; Fu W; Wang T; Abdallah R; Lim SJ; Bolejack V; Paller CJ; Carducci MA; Markowski MC; Eisenberger MA; Antonarakis ES
J Clin Oncol; 2021 Apr; 39(12):1371-1382. PubMed ID: 33617303
[TBL] [Abstract][Full Text] [Related]
7. Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma.
Motzer R; Alekseev B; Rha SY; Porta C; Eto M; Powles T; Grünwald V; Hutson TE; Kopyltsov E; Méndez-Vidal MJ; Kozlov V; Alyasova A; Hong SH; Kapoor A; Alonso Gordoa T; Merchan JR; Winquist E; Maroto P; Goh JC; Kim M; Gurney H; Patel V; Peer A; Procopio G; Takagi T; Melichar B; Rolland F; De Giorgi U; Wong S; Bedke J; Schmidinger M; Dutcus CE; Smith AD; Dutta L; Mody K; Perini RF; Xing D; Choueiri TK;
N Engl J Med; 2021 Apr; 384(14):1289-1300. PubMed ID: 33616314
[TBL] [Abstract][Full Text] [Related]
8. Angiokines Associated with Targeted Therapy Outcomes in Patients with Non-Clear Cell Renal Cell Carcinoma.
Armstrong AJ; Nixon AB; Carmack A; Yang Q; Eisen T; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; George DJ; Halabi S
Clin Cancer Res; 2021 Jun; 27(12):3317-3328. PubMed ID: 33593885
[TBL] [Abstract][Full Text] [Related]
9. Outcomes of systemic targeted therapy in recurrent renal cell carcinoma treated with adjuvant sunitinib.
de Velasco G; Ruiz-Granados Á; Reig O; Massari F; Climent Duran MA; Verzoni E; Graham J; Llarena R; De Tursi M; Donskov F; Iglesias C; Pandha HS; Garcia Del Muro X; Procopio G; Oudard S; Castellano D; Albiges L
BJU Int; 2021 Aug; 128(2):254-261. PubMed ID: 33547860
[TBL] [Abstract][Full Text] [Related]
10. Phase I Trial of Encapsulated Rapamycin in Patients with Prostate Cancer Under Active Surveillance to Prevent Progression.
Kemp Bohan PM; Chick RC; O'Shea AE; Vreeland TJ; Hickerson AT; Cindass JL; Ensley DC; Hale D; Clifton GT; Sohn VY; Thompson IM; Peoples GE; Liss MA
Cancer Prev Res (Phila); 2021 May; 14(5):551-562. PubMed ID: 33514567
[TBL] [Abstract][Full Text] [Related]
11. [Testosterone deficiency in the ageing male].
Jaschke NP; Rachner TD; Hofbauer LC
Dtsch Med Wochenschr; 2021 Feb; 146(3):141-145. PubMed ID: 33513645
[TBL] [Abstract][Full Text] [Related]
12. A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101.
Jelinek MJ; Foster NR; Zoroufy AJ; Schwartz GK; Munster PN; Seiwert TY; de Souza JA; Vokes EE
Oral Oncol; 2021 Mar; 114():105171. PubMed ID: 33513474
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of Sustained Minimal Residual Disease Negativity With Daratumumab-Combination Regimens in Relapsed and/or Refractory Multiple Myeloma: Analysis of POLLUX and CASTOR.
Avet-Loiseau H; San-Miguel J; Casneuf T; Iida S; Lonial S; Usmani SZ; Spencer A; Moreau P; Plesner T; Weisel K; Ukropec J; Chiu C; Trivedi S; Amin H; Krevvata M; Ramaswami P; Qin X; Qi M; Sun S; Qi M; Kobos R; Bahlis NJ
J Clin Oncol; 2021 Apr; 39(10):1139-1149. PubMed ID: 33513030
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine.
Nelson M; Winston A; Hill A; Mngqibisa R; Bassa A; Orkin C; Rassool M; Rodgers A; Teal V; Kumar S; Teppler H
AIDS; 2021 Apr; 35(5):759-767. PubMed ID: 33587439
[TBL] [Abstract][Full Text] [Related]
15. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
[TBL] [Abstract][Full Text] [Related]
16. Phase 1 study of bendamustine in combination with clofarabine, etoposide, and dexamethasone in pediatric patients with relapsed or refractory hematologic malignancies.
Jeha S; Crews KR; Pei D; Peyton M; Panetta JC; Ribeiro RC; Zhao X; Campbell P; Metzger ML; Yang JJ; Cheng C; Pui CH; Bhojwani D
Cancer; 2021 Jun; 127(12):2074-2082. PubMed ID: 33598942
[TBL] [Abstract][Full Text] [Related]
17. Effects of filgrastim versus pegfilgrastim on outcomes of DA-R-EPOCH for non-Hodgkin's lymphoma.
Roder L; Konrardy K; Grauer D; Hoffmann M
Support Care Cancer; 2021 Sep; 29(9):5075-5082. PubMed ID: 33594515
[TBL] [Abstract][Full Text] [Related]
18. Antimicrobial susceptibility of multidrug-resistant Pseudomonas aeruginosa isolated from drinking water and hospitalized patients in Jordan.
Tarazi YH; Abu-Basha E; Ismail ZB; Al-Jawasreh SI
Acta Trop; 2021 May; 217():105859. PubMed ID: 33582141
[TBL] [Abstract][Full Text] [Related]
19. Denosumab compared with zoledronic acid on PFS in multiple myeloma: exploratory results of an international phase 3 study.
Terpos E; Raje N; Croucher P; Garcia-Sanz R; Leleu X; Pasteiner W; Wang Y; Glennane A; Canon J; Pawlyn C
Blood Adv; 2021 Feb; 5(3):725-736. PubMed ID: 33560384
[TBL] [Abstract][Full Text] [Related]
20. [Short-Term Efficacy and Safety Profile of Generic Bortezomib in the Treatment of Multiple Myeloma].
Liao RQ; Lin XJ; Li XL; Ni X; Luo WF; Zhao P; Chen J; Wei J; Zou XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):137-144. PubMed ID: 33554810
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
